End TB with precision treatment!

European Respiratory Journal

Volumn 47, Issue 2, 2016, Pages 680-682

  Van Der Burgt, Evelien P M ^a   Sturkenboom, Marieke G G ^a   Bolhuis, Mathieu S ^a   Akkerman, Onno W ^a   Kosterink, Jos G W ^a   De Lange, Wiel C M ^a   Cobelens, Frank G J ^b,c   Van Der Werf, Tjip S ^a   Alffenaar, Jan Willem C ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b KNCV TUBERCULOSIS FOUNDATION   (Netherlands)

^c AMSTERDAM INSTITUTE FOR GLOBAL HEALTH AND DEVELOPMENT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ETHAMBUTOL; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; TUBERCULOSTATIC AGENT;

COST EFFECTIVENESS ANALYSIS; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG MONITORING; DRUG TREATMENT FAILURE; HUMAN; LETTER; LUNG TUBERCULOSIS; MAXIMUM PLASMA CONCENTRATION; OUTCOME ASSESSMENT; PERSONALIZED MEDICINE; PRIORITY JOURNAL; COMMUNICABLE DISEASE CONTROL; DEVELOPED COUNTRY; FEMALE; HEALTH; MALE; ORGANIZATION AND MANAGEMENT; TUBERCULOSIS;

ANTITUBERCULAR AGENTS; COMMUNICABLE DISEASE CONTROL; DEVELOPED COUNTRIES; FEMALE; GLOBAL HEALTH; HUMANS; MALE; TUBERCULOSIS;

EID: 84958064329     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/13993003.01285-2015     Document Type: Letter

References (10)

1. Lönnroth K, Migliori GB, Abubakar I, et al. Towards tuberculosis elimination: an action framework for low-incidence countries. Eur Respir J 2015; 45: 928-952.
2. Srivastava S, Pasipanodya JG, Meek C, et al. Multidrug-resistant tuberculosis not due to noncompliance but to between-patient pharmacokinetic variability. J Infect Dis 2011; 204: 1951-1959.
3. Smythe W, Khandelwal A, Merle C, et al. A semimechanistic pharmacokinetic-enzyme turnover model for rifampin autoinduction in adult tuberculosis patients. Antimicrob Agents Chemother 2012; 56: 2091-2098.
4. Conte JE Jr, Golden JA, Mcquitty M, et al. Effects of gender, AIDS, and acetylator status on intrapulmonary concentrations of isoniazid. Antimicrob Agents Chemother 2002; 46: 2358-2364.
5. Azuma J, Ohno M, Kubota R, et al. NAT2 genotype guided regimen reduces isoniazid-induced liver injury and early treatment failure in the 6-month four-drug standard treatment of tuberculosis: a randomized controlled trial for pharmacogenetics-based therapy. Eur J Clin Pharmacol 2013; 69: 1091-1101.
6. Tostmann A, Boeree MJ, Aarnoutse RE, et al. Antituberculosis drug-induced hepatotoxicity: concise up-to-date review. J Gastroenterol Hepatol 2008; 23: 192-202.
7. Satyaraddi A, Velpandian T, Sharma SK, et al. Correlation of plasma anti-tuberculosis drug levels with subsequent development of hepatotoxicity. Int J Tuberc Lung Dis 2014; 18: 188-195.
8. Pasipanodya JG, McIlleron H, Burger A, et al. Serum drug concentrations predictive of pulmonary tuberculosis outcomes. J Infect Dis 2013; 208: 1464-1473.
9. Vu DH, Alffenaar JW, Edelbroek PM, et al. Dried blood spots: a new tool for tuberculosis treatment optimization. Curr Pharm Des 2011; 17: 2931-2939.
10. Esposito S, Codecasa LR, Centis R. The role of therapeutic drug monitoring in individualised drug dosage and exposure measurement in tuberculosis and HIV co-infection. Eur Respir J 2015; 45: 571-574.